PYXS · Insider Trading
Pyxis Oncology, Inc. Common Stock
Every open-market purchase and sale reported by PYXS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-09 | GordonMD Long Biased Master Fund LP | 10%+ Owner | Buy | +28,688,000 deriv. | — |
| 2026-10-02 | GordonMD Global Investments LP | 10%+ Owner | Buy | +22,068,000 | — |
| 2026-09-08 | Thomas Civik | CEO & Chairman of the Board | A | +2,503,050 deriv. | — |
| 2026-08-20 | Jakob Dupont | Director | A | +46,000 deriv. | — |
| 2026-08-14 | Thomas Civik | Interim CEO | A | +250,956 deriv. | — |
| 2026-07-02 | Jakob Dupont | Director | MIXED | — | −$51.10K |
| 2026-03-25 | Rachel Humphrey | Director | A | +45,867 deriv. | — |
| 2026-03-25 | Santhosh Palani | Director | A | +45,867 deriv. | — |
| 2026-03-25 | Michael A Metzger | Director | A | +45,867 deriv. | — |
| 2026-03-25 | Freda C Lewis-Hall | Director | A | +45,867 deriv. | — |
| 2026-03-25 | Rachel Humphrey | Director | Sell | −15,496 | −$15.92K |
| 2026-03-25 | John L Flavin | Director | A | +45,867 deriv. | — |
| 2026-03-25 | Darren S Cline | Director | A | +45,867 deriv. | — |
| 2026-03-25 | Jitendra Wadhane | Prin Fin & Acct Officer | A | +109,461 | — |
| 2026-03-25 | Jakob Dupont | Director | A | +45,867 deriv. | — |
| 2026-02-05 | Thomas Civik | Interim CEO | A | +690,131 deriv. | — |
| 2025-04-02 | Jitendra Wadhane | SVP, Chief Accounting Officer | A | +263,782 deriv. | — |
| 2025-04-02 | Freda C Lewis-Hall | Director | A | +36,979 deriv. | — |
| 2025-04-02 | Rachel Humphrey | Director | A | +36,979 deriv. | — |
| 2025-04-02 | Santhosh Palani | Director | A | +36,979 deriv. | — |
| 2025-04-02 | Michael A Metzger | Director | A | +36,979 deriv. | — |
| 2025-04-02 | Lara Sullivan | President ,CEO & CMO | A | +918,308 deriv. | — |
| 2025-04-02 | Darren S Cline | Director | A | +36,979 deriv. | — |
| 2025-04-02 | Jakob Dupont | Director | A | +36,979 deriv. | — |
| 2025-04-02 | Thomas Civik | Director | A | +36,979 deriv. | — |
| 2025-04-02 | Pamela Ann Connealy | CFO & COO | A | +414,163 deriv. | — |
| 2025-04-02 | John L Flavin | Director | A | +36,979 deriv. | — |
| 2024-12-23 | Pamela Ann Connealy | CFO & COO | A | +310,000 deriv. | — |
| 2024-12-23 | Lara Sullivan | Chief Executive Officer | A | +1,135,000 deriv. | — |
| 2024-12-23 | Jitendra Wadhane | SVP, Chief Accounting Officer | A | +150,000 deriv. | — |
| 2024-11-27 | Pamela Ann Connealy | CFO & COO | Buy | +88,850 | +$174.36K |
| 2024-06-10 | Michael A Metzger | Director | A | +70,683 deriv. | — |
| 2024-06-07 | Santhosh Palani | Director | A | +6,000 | — |
| 2024-03-28 | Lara Sullivan | Chief Executive Officer | A | +1,071,242 deriv. | — |
| 2024-03-28 | Thomas Civik | Director | A | +44,024 deriv. | — |
| 2024-03-28 | John L Flavin | Director | A | +35,219 | — |
| 2024-03-28 | Rachel Humphrey | Director | A | +38,741 | — |
| 2024-03-28 | Freda C Lewis-Hall | Director | A | +35,219 | — |
| 2024-03-28 | Jakob Dupont | Director | A | +38,741 | — |
| 2024-03-28 | Pamela Ann Connealy | CFO & COO | A | +328,710 | — |
| 2024-03-28 | Darren S Cline | Director | A | +35,219 | — |
| 2024-03-28 | Jitendra Wadhane | SVP, Chief Accounting Officer | A | +131,484 | — |
| 2024-03-13 | Santhosh Palani | Director | A | +69,760 deriv. | — |
| 2023-12-29 | Ken Kobayashi | Chief Medical Officer | A | +554,392 deriv. | — |
| 2023-11-30 | Pamela Ann Connealy | CFO and COO | F | −36,949 | −$51.73K |
| 2023-11-17 | Jitendra Wadhane | Chief Accounting Officer | A | +40,000 | — |
| 2023-09-28 | Pamela Ann Connealy | CFO and COO | Buy | +8,000 | +$14.96K |
| 2023-09-27 | Pamela Ann Connealy | CFO and COO | Buy | +6,426 | +$11.87K |
| 2023-09-27 | Jitendra Wadhane | Chief Accounting Officer | Buy | +2,500 | +$4.67K |
| 2023-09-26 | Jakob Dupont | Director | A | +392,461 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| GordonMD Global Investments LP | 10%+ Owner | 15,541,909 | $26.58M |
| Lara Sullivan | President ,CEO & CMO | 2,412,423 | $4.13M |
| Pamela Ann Connealy | CFO & COO | 2,226,036 | $3.81M |
| Jitendra Wadhane | Prin Fin & Acct Officer | 512,882 | $877.03K |
| John L Flavin | Director | 413,015 | $706.26K |
| Darren S Cline | Director | 251,405 | $429.90K |
| Freda C Lewis-Hall | Director | 241,405 | $412.80K |
| Thomas Civik | CEO & Chairman of the Board | 221,886 | $379.43K |
| Rachel Humphrey | Director | 95,405 | $163.14K |
| Jakob Dupont | Director | 38,741 | $66.25K |
| Santhosh Palani | Director | 6,000 | $10.26K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PYXS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.